Circulating Biomarkers in Hypertrophic Cardiomyopathy

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2022 Nov 16

PMID 36382968

Authors

Eldon L Matthia

Michael L Setteducato

Mohammed Elzeneini

Nicholas Vernace

Michael Salerno

Christopher M Kramer

Ellen C Keeley

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.

Citing Articles

Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.

Llamas-Esperon G, Berrios-Barcenas E, Cossio-Aranda J, Guerra-Lopez A, Magana-Serrano J, Iturralde-Torres P Arch Cardiol Mex. 2025; 94(Supl 4):1-75.

PMID: 39928711 PMC: 11824882. DOI: 10.24875/ACM.M25000098.

Circulating microRNA as promising biomarkers in hypertrophic cardiomyopathy: can advanced cardiac magnetic resonance unlock new insights in research?.

Chumakova O, Mershina E Exp Biol Med (Maywood). 2025; 249():10334.

PMID: 39744621 PMC: 11688189. DOI: 10.3389/ebm.2024.10334.

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.

Sarwer K, Lashari S, Rafaqat N, Maher , Raheem A, Rehman M Egypt Heart J. 2024; 76(1):156.

PMID: 39645546 PMC: 11625047. DOI: 10.1186/s43044-024-00587-y.

Biomarkers in cardiogenic shock: old pals, new friends.

Jozwiak M, Lim S, Si X, Monnet X Ann Intensive Care. 2024; 14(1):157.

PMID: 39414666 PMC: 11485002. DOI: 10.1186/s13613-024-01388-x.

Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.

Coats C, Masri A, Barriales-Villa R, Abraham T, Brinkley D, Claggett B Eur Heart J. 2024; 45(42):4464-4478.

PMID: 39217447 PMC: 11544315. DOI: 10.1093/eurheartj/ehae590.

References

Fernandes F, Arteaga-Fernandez E, Antunes M, Buck P, Marsiglia J, Matsumoto A . Plasma pro-B-type natriuretic peptide testing as a screening method for hypertrophic cardiomyopathy. J Card Fail. 2012; 18(7):564-8. DOI: 10.1016/j.cardfail.2012.04.005. View

Shim C, Ha J, Choi E, Lee H, Moon S, Kim J . Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J. 2010; 39(12):519-24. PMC: 2801459. DOI: 10.4070/kcj.2009.39.12.519. View

Yang H, Liu X, Qu C, Shi S, Liang J, Yang B . Usefulness of Red Blood Cell Distribution Width to Predict Heart Failure Hospitalization in Patients with Hypertrophic Cardiomyopathy. Int Heart J. 2018; 59(4):779-785. DOI: 10.1536/ihj.17-507. View

Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T . Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39(10):1657-63. DOI: 10.1016/s0735-1097(02)01813-2. View

Kubo T, Okumiya T, Baba Y, Hirota T, Tanioka K, Yamasaki N . Erythrocyte creatine as a marker of intravascular hemolysis due to left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Cardiol. 2015; 67(3):274-8. DOI: 10.1016/j.jjcc.2015.05.005. View

Ntelios D, Georgiou E, Alexouda S, Malousi A, Efthimiadis G, Tzimagiorgis G . A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy. Heart Fail Rev. 2021; 27(1):281-294. DOI: 10.1007/s10741-021-10084-y. View

Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y . Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J. 2011; 75(4):919-26. DOI: 10.1253/circj.cj-10-0782. View

Ingles J, Burns C, Barratt A, Semsarian C . Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection. Circ Cardiovasc Genet. 2015; 8(6):852-9. DOI: 10.1161/CIRCGENETICS.115.001093. View

Ho C, Abbasi S, Neilan T, Shah R, Chen Y, Heydari B . T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013; 6(3):415-22. PMC: 3769196. DOI: 10.1161/CIRCIMAGING.112.000333. View

10.

Nakagawa Y, Nishikimi T, Kuwahara K . Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2018; 111:18-25. DOI: 10.1016/j.peptides.2018.05.012. View

11.

Fucikova A, Lenco J, Tambor V, Rehulkova H, Pudil R, Stulik J . Plasma concentration of fibronectin is decreased in patients with hypertrophic cardiomyopathy. Clin Chim Acta. 2016; 463:62-66. DOI: 10.1016/j.cca.2016.09.024. View

12.

Tesic M, Seferovic J, Trifunovic D, Djordjevic-Dikic A, Giga V, Jovanovic I . N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy. J Cardiol. 2017; 70(4):323-328. DOI: 10.1016/j.jjcc.2017.02.008. View

13.

McGorrian C, Lyster S, Roy A, Tarrant H, Codd M, Doran P . Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study. BMC Cardiovasc Disord. 2013; 13:70. PMC: 3849957. DOI: 10.1186/1471-2261-13-70. View

14.

Hiremath P, Lawler P, Ho J, Correia A, Abbasi S, Kwong R . Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy. Circ Heart Fail. 2016; 9(9). PMC: 5024718. DOI: 10.1161/CIRCHEARTFAILURE.116.003026. View

15.

Zhang C, Liu R, Yuan J, Cui J, Hu F, Yang W . Significance and Determinants of Cardiac Troponin I in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2015; 116(11):1744-51. DOI: 10.1016/j.amjcard.2015.09.006. View

16.

Suthahar N, Meijers W, Sillje H, Ho J, Liu F, de Boer R . Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018; 8(3):593-609. PMC: 5771079. DOI: 10.7150/thno.22196. View

17.

Emet S, Dadashov M, Sonsoz M, Cakir M, Yilmaz M, Elitok A . Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Am J Med Sci. 2018; 356(6):537-543. DOI: 10.1016/j.amjms.2018.08.013. View

18.

Hu D, Xu J, Du W, Zhang J, Zhong M, Zhou Y . Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients. Int J Cardiovasc Imaging. 2016; 32(12):1725-1733. DOI: 10.1007/s10554-016-0958-1. View

19.

Guo Y, Wu X, Zheng X, Lu J, Wang S, Huang X . Usefulness of Preoperative Transforming Growth Factor-Beta to Predict New Onset Atrial Fibrillation After Surgical Ventricular Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2017; 120(1):118-123. DOI: 10.1016/j.amjcard.2017.03.252. View

20.

Ho J, Shi L, Day S, Colan S, Russell M, Towbin J . Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart. 2017; 4(2):e000615. PMC: 5687543. DOI: 10.1136/openhrt-2017-000615. View